User login
Article Type
Changed
Thu, 12/15/2022 - 18:06
Display Headline
Immunotherapy moves into the breast cancer landscape
At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(1)
Topics
Page Number
30-33
Legacy Keywords
breast cancer, immunotherapy, pembrolizumab, SOFT trial, ovarian supression, tamoxifen, fulvestrant
Sections
Article PDF
Article PDF
At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(1)
Issue
The Journal of Community and Supportive Oncology - 13(1)
Page Number
30-33
Page Number
30-33
Topics
Article Type
Display Headline
Immunotherapy moves into the breast cancer landscape
Display Headline
Immunotherapy moves into the breast cancer landscape
Legacy Keywords
breast cancer, immunotherapy, pembrolizumab, SOFT trial, ovarian supression, tamoxifen, fulvestrant
Legacy Keywords
breast cancer, immunotherapy, pembrolizumab, SOFT trial, ovarian supression, tamoxifen, fulvestrant
Sections
Citation Override
JCSO 2015:13;30-33
Disallow All Ads
Alternative CME
Article PDF Media
Document